News
News from us and our partners
Tags
Topics
0 results
- News
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
- News
Sitryx Reports Positive Phase 1b Results for First-in-Class Oral PKM2 Modulator SYX-5219 in Patients with Moderate to Severe Atopic Dermatitis
- News
GenSight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
- News
Sensorion Announces the Appointment of Louis J. Arcudi III as Chief Financial Officer
- News
GenSight Biologics Reports Cash Position as of September 30, 2026
- News
Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)
- News
Rezera Announces Positive RESOLVE-2 Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile for Ruvonoflast in Combination with Semaglutide
- News
TISSIUM® Announces First U.S. Patients Treated with the ECLIPSIUM® System in UNITE Clinical Trial
- News
AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
- News
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
- News
Rezera announces phase 1 results for Trabzanoflast, which was generally well tolerated and demonstrated high central nervous system exposure (CNS)
- News
GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
- News
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
- News
Redx Announces Design of ROCKETEER Phase 2 Trial for RXC008 in Fibrostenotic Crohn’s Disease
- News
Sofinnova Partners closes oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies